Evidence map›Paper›PMID 29727402›Full record

ArticleInvestigative radiology2018

Targeted Imaging of Renal Fibrosis Using Antibody-Conjugated Gold Nanoparticles in Renal Artery Stenosis.

Xiang-Yang Zhu, Xiangyu Zou, Rahul Mukherjee, Zhicong Yu, Christopher M Ferguson, Wei Zhou, Cynthia H McCollough, Lilach O Lerman

Open access · greenAbstract read
In one paragraph

Article in Investigative radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Noninvasive assessment of renal fibrosis by magnetic resonance imaging and ultrasound techniques.Translational research : the journal of laboratory and clinical medicine · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Xiang-Yang ZhuFrom the Division of Nephrology and Hypertension and.
Xiangyu ZouFrom the Division of Nephrology and Hypertension and.
Rahul MukherjeeFrom the Division of Nephrology and Hypertension and.
Zhicong YuDepartment of Radiology, Mayo Clinic, Rochester, MN.
Christopher M FergusonFrom the Division of Nephrology and Hypertension and.
Wei ZhouDepartment of Radiology, Mayo Clinic, Rochester, MN.
Cynthia H McColloughDepartment of Radiology, Mayo Clinic, Rochester, MN.
Lilach O LermanFrom the Division of Nephrology and Hypertension and.
Hypertension Institute · USMayo Clinic in Arizona · US

Funding

Photon-Counting Spectral CT to Reduce Dose and Detect Early Vascular DiseaseR01EB016966 · NIBIB · MAYO CLINIC ROCHESTER · PI MCCOLLOUGH, CYNTHIA H · 2013 to 2017
$5.1M
CT imaging for the assessment of kidney injury distal to renal artery stenosisR01DK073608 · NIDDK · MAYO CLINIC ROCHESTER · PI LERMAN, LILACH O · 2006 to 2015
$3.1M
Ultrasound Shockwave Therapy for Post-Stenotic Microvascular RemodelingR01HL123160 · NHLBI · MAYO CLINIC ROCHESTER · PI LERMAN, AMIR, LERMAN, LILACH O · 2015 to 2018
$3.0M
MSC-derived microvesicles in metabolic syndrome and renovascular diseaseR01DK102325 · NIDDK · MAYO CLINIC ROCHESTER · PI LERMAN, LILACH O · 2015 to 2018
$2.8M
EXTRAMURAL RES FACIL IMPROVEMENT PROG: POLYCYSTIC KIDNEY DISEASE, RENAL STUDIES,C06RR018898 · NCRR · MAYO CLINIC · PI BURNETT, JOHN C · 2004 to 2004
$2.3M
Noninvasive assessment of renal fibrosis using magnetization transfer MRIU01DK104273 · NIDDK · MAYO CLINIC ROCHESTER · PI LERMAN, LILACH O · 2014 to 2018
$1.8M
NCRR NIH HHS C06 RR018898NHLBI NIH HHS R01 HL123160NIBIB NIH HHS R01 EB016966NIDDK NIH HHS R01 DK073608NIDDK NIH HHS R01 DK102325NIDDK NIH HHS U01 DK104273
6 · The paper itself

Abstract

objectivesThe ability to determine the severity of renal fibrosis, which is involved in most chronic kidney diseases, may be beneficial for monitoring disease progression and management. The aim of this study was to assess a new method involving gold nanoparticles conjugated to an anti-collagen-I antibody (Co-I-AuNPs) as a computed tomography (CT) imaging contrast for the evaluation of renal fibrosis in situ. MATERIALS AND

methodsGold nanoparticles conjugated to an anti-collagen-I antibody were prepared using gold chloride reduction with sodium citrate and coated with polyethylene glycol (PEG), and their size was determined by electron microscopy and nanoparticle tracking analysis. Anti-collagen-I antibody was then conjugated to PEG-SH/COOH on the AuNP surface. The success of antibody conjugation was tested in vitro using collagen-coated plate and mouse stenotic kidney sections and in vivo using micro-CT and multidetector CT imaging.

resultsBare AuNPs were 18.7 ± 0.6 nm and PEG-coated AuNPs were 45.3 ± 0.1 nm in size. In vitro, Co-I-AuNPs specifically bound to both a collagen-coated plate and mouse fibrotic kidneys. Furthermore, the stenotic mouse kidney showed increased Co-I-AuNPs retention compared with the contralateral kidney (59.3 ± 5.1 vs 45.1 ± 1.7 HU, P = 0.05), which correlated with its collagen deposition. Micro-CT also detected gold signals in situ in the Co-I-AuNP-injected kidney, which colocalized with histological trichrome staining.

conclusionGold nanoparticles conjugated to an anti-collagen-I antibody are able to visualize kidney fibrosis in vitro and in situ and may be useful for nondestructive quantification of tissue fibrosis.

Indexed as

Antibodies, MonoclonalContrast MediaGoldMetal NanoparticlesAnimalsDisease Models, AnimalFibrosisKidneyMiceRadiographic Image EnhancementRenal Artery ObstructionSeverity of Illness IndexTomography, X-Ray ComputedAntibodies, MonoclonalContrast MediaGold

Identifiers

PMID29727402
PMCPMC6123257
OpenAlexW2801508403

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.